There are obvious difficulties in performing a therapeutic trial mainly due to the rarity of the disease.[1] Park et al[14] first reported a 7-year-old boy treated with surgical resection and adjuvant IFN-α2b immunotherapy for pediatric PEComa of the ascending colon. This evidence concerns the gene IFNA2 and neoplasm with perivascular epithelioid cell differentiation.